Furthermore, if p53-directed targeted therapy shows promising results in metastatic GISTs, the incorporation of p53-directed targeted therapy may be considered for development in the neoadjuvant setting for high-risk GIST, in combination with KIT/PDGFRA targeted therapy to increase response rate and maximize tumor shrinkage (Figure 1). The gene discussed is TP53; the disease is neoplasm.